Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 1b Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Dose of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines

Trial Profile

A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 1b Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Dose of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eptinezumab (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Alder Biopharmaceuticals
  • Most Recent Events

    • 06 Jun 2021 Results of pooled analysis from 4 studies: (NCT01772524, NCT02275117, NCT02559895 (PROMISE-1), and NCT02974153 (PROMISE-2)) assessing the cardiovascular safety profile, CV risk in patients with migraine and mild to moderate CV risk factors, with few CV- related TEAEs and in few patients starting new or changing their dose of CV medication, presented at the 63rd Annual Scientific Meeting of the American Headache Society.
    • 10 Sep 2017 Results of this trial and 2 other trials (refer CTP: 250744, 259778) were presented at the 2017 International Headache Society
    • 15 May 2015 According to an Alder Biopharmaceuticals media release, data from this trial were presented at the 17th Congress of the International Headache Society.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top